These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9746584)

  • 1. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.
    Byrne MP; Smith TJ; Montgomery VA; Smith LA
    Infect Immun; 1998 Oct; 66(10):4817-22. PubMed ID: 9746584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.
    Byrne MP; Titball RW; Holley J; Smith LA
    Protein Expr Purif; 2000 Apr; 18(3):327-37. PubMed ID: 10733887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL; Gao S; Kang L; Nie C; Wang JL
    Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
    Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
    Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
    Villaflores OB; Hsei CM; Teng CY; Chen YJ; Wey JJ; Tsui PY; Shyu RH; Tung KL; Yeh JM; Chiao DJ; Wu TY
    J Virol Methods; 2013 Apr; 189(1):58-64. PubMed ID: 23313783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
    Shi DY; Chen BY; Mao YY; Zhou G; Lu JS; Yu YZ; Zhou XW; Sun ZW
    Hum Vaccin Immunother; 2019; 15(3):755-760. PubMed ID: 30433836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of recombinant vaccines for botulinum neurotoxin.
    Smith LA
    Toxicon; 1998 Nov; 36(11):1539-48. PubMed ID: 9792170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
    Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.
    Ben David A; Torgeman A; Barnea A; Zichel R
    Protein Expr Purif; 2015 Jun; 110():122-9. PubMed ID: 25727047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
    Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
    Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.
    Lee JS; Pushko P; Parker MD; Dertzbaugh MT; Smith LA; Smith JF
    Infect Immun; 2001 Sep; 69(9):5709-15. PubMed ID: 11500447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris.
    Potter KJ; Zhang W; Smith LA; Meagher MM
    Protein Expr Purif; 2000 Aug; 19(3):393-402. PubMed ID: 10910730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.
    Shone C; Agostini H; Clancy J; Gu M; Yang HH; Chu Y; Johnson V; Taal M; McGlashan J; Brehm J; Tong X
    Infect Immun; 2009 Jul; 77(7):2795-801. PubMed ID: 19398544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.
    Ben David A; Diamant E; Barnea A; Rosen O; Torgeman A; Zichel R
    Clin Vaccine Immunol; 2013 Aug; 20(8):1266-73. PubMed ID: 23761665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.